Qingkui Wang, Yuanyuan Zhang, Dan Shao, Gerilechaolumen, Hongying Zhang, Xue Zhao, Hui Jiang* 


Department of Respiratory and Critical Care Medicine, People's Hospital of Xing'an League of Inner Mongolia, Ulanhot, PR China


Objective: to analyse the efficacy of naloxone in the treatment of chronic obstructive pulmonary disease (COPD) with type II respiratory failure. 

Methods: eighty-six patients with COPD and type II respiratory failure who were admitted to our hospital from January 20 to September 2019 were enrolled in the study. They were divided into reference group and observation group according to the treatment method, with 43 cases in each group. Routine treatment was used for the reference group, while the observation group was treated with naloxone on the basis of regular quality, and the clinical effects on the two groups were compared. 

Results: there was no significant difference between the arterial blood gas indexes of the two groups before treatment (P>0.05). However, the arterial blood gas indexes of the two groups were significantly improved after treatment, and the difference was statistically significant (P<0.05). Furthermore, after treatment, the improvement was significantly greater in the observation group, compared with the reference group (P<0.05). The total effective rate of clinical treatment was 74.42% in the reference group and 93.02% in the observation group; the difference between the two groups was statistically significant (P<0.05). Furthermore, although the incidence of adverse reactions was slightly increased in the observation group (20.93%), compared with the control group (16.28%), the difference was not statistically significant (P>0.05). 

Conclusion: Compared with the conventional treatment of patients with COPD and type II respiratory failure, naloxone treatment led to quantifiably improved results, as determined by analysis of arterial blood gas index and clinical efficacy. Notably, the use of naxolone did not significantly increase the incidence of adverse reactions and its clinical use value was higher, compared with conventional treatment.


Naloxone, chronic obstructive pulmonary disease, type II respiratory failure.